Atosiban

CAS 90779-69-4 0 current records 1 historicalProtein

Who holds supplier records for Atosiban? No organisation holds a current US Type II DMF or EU CEP for Atosiban in the registers PharmaTek covers. A further 1 organisation has only historical (inactive) DMF filings.

Most records are filed under another form of this substance: Atosiban Acetate (2 current sources). A DMF or CEP is listed under the form it names.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 11 Nov 2026. How we read these records

Cite as: PharmaTek, “Atosiban: DMF and CEP holder records”, record as of 11 Nov 2026, pharmatek.co.uk/directory/api/atosiban

Reading the evidence

  • No current DMF or CEP on record

    Only historical filings exist in the covered registers. Any of these organisations may or may not supply today; confirm directly.

Current records (0)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Atosiban. Country is the organisation's recorded country, not necessarily the manufacturing site.

Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.

Need Atosiban sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Atosiban are no longer active. These show a past filing, not current supply.

Show all 1 historical record

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Atosiban is a protein active pharmaceutical ingredient (ChEMBL CHEMBL382301).

Chemical identity

IUPAC name
(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
Canonical SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
InChIKey
VWXRQYYUEIYXCZ-OBIMUBPZSA-N
Synonyms
Antocile, Antocin, Antocin ii, Atosiban, CAP-449, CAP-476, CAP-581, F-314, ORF 22164, ORF-22164, RW-22164, RWJ 22164

Record history

PharmaTek records which organisations hold a current DMF or CEP for Atosiban every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

What do the historical Atosiban records mean?

1 organisation has only inactive Type II DMFs for Atosiban. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Atosiban supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Atosiban?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.